Start:
November 30, 2015
End:
March 31, 2025
Enrollment:
1340
This clinical trial will test whether two investigational drugs, CAD106 and CNP520, administered separately, can prevent or delay Alzheimer's disease symptoms in people at high risk of developing dementia based on their age and genetic status.
Minimum Age: 60 Years
Maximum Age: 75 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Who Is the General Study Contact?
For more information about this trial, contact Novartis Pharmaceuticals toll-free at 1-888-669-6682 or info@generationprogram.com
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Novartis Pharmaceuticals
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT02565511
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health